Community | Kisaco Research

Our Network

All of our events are only possible because of our network of speakers, advisors, partners and attendees who continue to help develop and inform our series, ensuring that we remain the industry's most premier and relevant innovation series. Read more about the global Animal Health Innovation Series community below

ADVISORY BOARD

The Global Advisory Board is a prestigious group of individuals with extensive experience in the animal health industry. This group is responsible for guiding the production and development of the global Animal Health, Nutrition & Technology Innovation Series.

For enquiries please email [email protected]

Author:

Jamie Brannan

Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics
Zoetis

Jamie Brannan

Executive Vice President and Group President International Operations, Aquaculture and Global Diagnostics
Zoetis

Author:

Aaron Schacht

CEO
BiomEdit

Aaron Schacht

CEO
BiomEdit

Author:

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan Mackay

Executive Partner and Founder
GHO Capital

Author:

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

Linda Rhodes

VMD, PhD, Independent and ex-CSO
Independent Animal Health

Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Author:

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco

Ellen de Brabander

Executive Vice President R&D and Innovation
Elanco

Author:

Rob Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD Animal Health

Rob Kelly

Senior Vice President, Commercial Leader for EURAM Region
MSD Animal Health

Author:

Sébastien Huron

Chief Executive Officer
Virbac

Sébastien Huron

Chief Executive Officer
Virbac

Author:

Thomas Zerzan

President Companion Animal
Phibro Animal Health

Thomas Zerzan

President Companion Animal
Phibro Animal Health

STRATEGIC PARTNERS

From the market leading Animal Health and Pharmaceutical Companies to the most well respected CROs, CMOs, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors, our Strategic Partners continue to play a pivotal role in how we help shape the future of Animal Health. For more information on how to become a strategic partner, please visit our Marketing Solutions page

TESTIMONIALS & SUCCESS STORIES

SUCCESS STORIES

Hear from industry professionals about their experiences with our events and how they've benefited company growth.

    Contact Us

    Kisaco Research
    Registered office address: 41a Maltby Street, London, SE1 3PA
    +44 (0)20 3696 2920 | [email protected]
    Place of registration: London, United Kingdom
    Company number: 09316521

    We need some information to know how best to respond to your request below.

    To prevent automated spam submissions leave this field empty.

    Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

    User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

    For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.